Human papillomavirus vaccine - MediGene/Virionics
Alternative Names: CVLP tumour vaccine - MediGene/Virionics; HPV-16 L1-E7 chimeric VLP - MediGene/Virionics; Human papillomavirus type 16 L1-E7 chimeric virus-like particle vaccine - MediGene/Virionics; PapViRxLatest Information Update: 25 Sep 2021
At a glance
- Originator MediGene AG
- Developer MediGene AG; Virionics
- Class Cancer vaccines; Papillomavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Anal intraepithelial neoplasia; Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections; Vulvar intraepithelial neoplasia
Most Recent Events
- 11 Mar 2008 Preclinical trials in Cervical intraepithelial neoplasia in USA (unspecified route)
- 11 Mar 2008 Preclinical trials in Human papillomavirus infections in USA (unspecified route)
- 04 Apr 2006 Human papillomavirus vaccine licensed to Virionics worldwide